Cleveland Clinic Lerner Com-cwru

Organization

People

Sources: reporter.nih.gov

Grants and prizes

  • National Institute of Neurological Disorders and Stroke

    R01, Dark GPCR signaling underlying the Microbiome-Gut-Brain Axis for Alzheimer's Disease and Related Dementia, R01NS133812, $762K, 2023–2027, Sep 19, 2026

  • National Institute of Neurological Disorders and Stroke

    K23, Healthy Aging in People with Epilepsy Program (HAP-E): Closing the Gap in Geriatric Epilepsy Care, K23NS138682, $54K, 2026–2027, Sep 18, 2026

  • National Eye Institute

    R01, Epigenetic regulation of optic nerve head astrocyte reactivity in glaucoma, R01EY039258, $570K, 2026–2031, Sep 18, 2026

  • National Heart, Lung, and Blood Institute

    K23, Frailty and Resiliency in Older Adults with Acute Myocardial Infarction, K23HL153771, $183K, 2020–2027, Sep 17, 2026

  • National Institute on Aging

    R50, Building The Alzheimer's Cell Atlas to Decipher Disease Complexity and Expedite Drug Development, R50AG099852, $132K, 2026–2029, Sep 8, 2026

  • National Institute of Diabetes and Digestive and Kidney Diseases

    U01, Prospective evaluation of outcomes in cirrhosis of different etiologies: impact of HIV infection and simvastatin therapy, U01DK130180, $623K, 2021–2027, Sep 7, 2026

  • National Cancer Institute

    R01, CHAMP: Cervical Cancer Prevention Using HPV Testing with a Mobile Testing Platform, R01CA299083, $574K, 2026–2031, Sep 7, 2026

  • National Institute on Aging

    R01, Endophenotype Network-based Approaches to Prediction and Functional Validation of in Silico Drug Repurposing for Alzheimer's Disease, R01AG066707, $781K, 2020–2031, Sep 4, 2026

  • National Institute on Aging

    P30, Cleveland Alzheimer's Disease Research Center, P30AG072959, $4.3M, 2021–2031, Aug 31, 2026

  • NIH Office of the Director

    OT2, Cellular-level Vascular Oculomics (CVO) for monitoring systemic vascular health, OT2OD038128, $1.6M, 2026–2027, Aug 28, 2026

  • National Institute on Aging

    R01, Neural Mechanisms underlying the benefits of Aerobic Exercise in Advanced Parkinson's disease, R01AG092298, $655K, 2025–2030, Aug 28, 2026

  • National Heart, Lung, and Blood Institute

    U24, Master - 2/2 Empaglifozin To Improve Right Ventricular Function in Pulmonary Arterial Hypertension, U24HL175028, $363K, 2024–2030, Aug 24, 2026

  • National Heart, Lung, and Blood Institute

    UH3, 1/2 Empagliflozin to Improve Right Ventricular Function in Pulmonary Arterial Hypertension, UH3HL175041, $815K, 2024–2030, Aug 24, 2026

  • National Institute on Aging

    R33, Precision Medicine Digital Twins for Alzheimer’s Target and Drug Discovery and Longevity, R33AG083003, $563K, 2023–2028, Aug 20, 2026

  • National Heart, Lung, and Blood Institute

    R01, Improving adherence to cardiovascular risk reducing regimens through clinical decision support, R01HL178795, $824K, 2026–2030, Aug 6, 2026

  • National Institute on Aging

    R01, Randomized Trial of Assisted Ambulation to Improve Health Outcomes for Older Medical Inpatients, R01AG073278, $1.4M, 2022–2027, Jul 14, 2026

  • National Heart, Lung, and Blood Institute

    K08, Population Assessments of Aggregate Genetic Risk for DilatedýCardiomyopathy, K08HL153937, $133K, 2021–2026, Jun 25, 2026

  • National Institute of Neurological Disorders and Stroke

    F31, Investigating the role of sulfide oxidation and declining hydrogen sulfide in glioblastoma, F31NS141426, $34.1K, 2025–2028, Jun 23, 2026

  • National Institute on Aging

    R01, Immune cell activation and associated blood brain barrier changes across different stages of Alzheimer's disease, R01AG078763, $766K, 2022–2028, May 28, 2026

  • National Institute on Aging

    R01, Alzheimer's Disease and Related Dementia-like Sequelae of SARS-CoV-2 Infection: Virus-Host Interactome, Neuropathobiology, and Drug Repurposing, R01AG082211, $781K, 2023–2028, May 11, 2026

Sources: reporter.nih.gov